Peptides最新文献_第9页

Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy 一种强效长效牛蛙 GLP-1 类似物在 GLP-1 和淀粉样蛋白联合疗法中的鉴定和实用性探索

IF 3 4区医学

Peptides Pub Date : 2024-04-04 DOI: 10.1016/j.peptides.2024.171203

Xiao Sun , Dawei Yang , Yan Li , Jingjing Shi , Xiaolong Zhang , Tingzhuang Yi

{"title":"Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy","authors":"Xiao Sun , Dawei Yang , Yan Li , Jingjing Shi , Xiaolong Zhang , Tingzhuang Yi","doi":"10.1016/j.peptides.2024.171203","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171203","url":null,"abstract":"<div><p>This study assesses the efficacy of an innovative therapeutic approach that combines GLP-1 and amylin analogues for weight reduction. Focusing on GLP-1 analogues from bullfrog (<em>Rana catesbeiana</em>), we designed ten bGLP-1 analogues with various modifications. Among them, bGLP-10 showed high potency in binding and activating GLP-1 receptors, with superior albumin affinity. In diet-induced obesity (DIO) mice fed a high-fat diet, bGLP-10 demonstrated significant superiority over semaglutide in reducing blood sugar and food intake at a dose of 10 nmol/kg (P < 0.001). Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone. Furthermore, the bGLP-10 and cagrilintide combination exhibited superior glucose control and liver lipid management compared to the semaglutide-cagrilintide combination (P < 0.001). These results highlight bGLP-10’s potential in GLP-1 and amylin-based therapies and suggest exploring more GLP-1 analogues from natural sources for anti-obesity and anti-diabetic treatments.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171203"},"PeriodicalIF":3.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the GLP-2 receptor in the management of obesity 靶向 GLP-2 受体治疗肥胖症

IF 3 4区医学

Peptides Pub Date : 2024-04-03 DOI: 10.1016/j.peptides.2024.171210

Thorir G. Pálsson , Hannah Gilliam-Vigh , Benjamin A.H. Jensen , Palle B. Jeppesen , Asger B. Lund , Filip K. Knop , Casper K. Nielsen

{"title":"Targeting the GLP-2 receptor in the management of obesity","authors":"Thorir G. Pálsson , Hannah Gilliam-Vigh , Benjamin A.H. Jensen , Palle B. Jeppesen , Asger B. Lund , Filip K. Knop , Casper K. Nielsen","doi":"10.1016/j.peptides.2024.171210","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171210","url":null,"abstract":"<div><p>Recent advancements in understanding glucagon-like peptide 2 (GLP-2) biology and pharmacology have sparked interest in targeting the GLP-2 receptor (GLP-2R) in the treatment of obesity. GLP-2 is a proglucagon-derived 33-amino acid peptide co-secreted from enteroendocrine L cells along with glucagon-like peptide 1 (GLP-1) and has a range of actions via the GLP-2R, which is particularly expressed in the gastrointestinal tract, the liver, adipose tissue, and the central nervous system (CNS). In humans, GLP-2 evidently induces intestinotrophic effects (i.e., induction of intestinal mucosal proliferation and improved gut barrier function) and promotes mesenteric blood flow. However, GLP-2 does not seem to have appetite or food intake-reducing effects in humans, but its gut barrier-promoting effect may be of interest in the context of obesity. Obesity is associated with reduced gut barrier function, increasing the translocation of proinflammatory gut content to the circulation. This phenomenon constitutes a strong driver of obesity-associated systemic low-grade inflammation, which in turn plays a major role in the development of most obesity-associated complications. Thus, the intestinotrophic and gut barrier-improving effect of GLP-2, which in obese rodent models shows strong anti-inflammatory potential, may, in combination with food intake-reducing strategies, e.g., GLP-1 receptor (GLP-1) agonism, be able to rectify core pathophysiological mechanism of obesity. Here, we provide an overview of GLP-2 physiology in the context of obesity pathophysiology and review the pharmacological potential of GLP-2R activation in the management of obesity and related comorbidities.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171210"},"PeriodicalIF":3.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0196978124000639/pdfft?md5=a7999597c0a995b795d7cb5be4d5abde&pid=1-s2.0-S0196978124000639-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140350862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications 鼻内催产素作为焦虑症和自闭症的治疗方法：从亚临床应用到临床应用

IF 3 4区医学

Peptides Pub Date : 2024-04-03 DOI: 10.1016/j.peptides.2024.171211

Hailian Yin , Meiyun Jiang , Tao Han , Xiaolei Xu

{"title":"Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications","authors":"Hailian Yin , Meiyun Jiang , Tao Han , Xiaolei Xu","doi":"10.1016/j.peptides.2024.171211","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171211","url":null,"abstract":"<div><p>Animal and human studies have demonstrated that intranasal oxytocin (OT) can penetrate the brain and induce cognitive, emotional, and behavioral changes, particularly in social functioning. Consequently, numerous investigations have explored the potential of OT as a treatment for anxiety and autism, conditions characterized by social deficits. Although both subclinical and clinical studies provide converging evidence of the therapeutic effects of OT in reducing anxiety levels and improving social symptoms in autism, results are not always consistent. Additionally, the pharmacological mechanism of OT requires further elucidation for its effective clinical application. Therefore, this review aims to examine the contentious findings concerning the effects of OT on anxiety and autism, offer interpretations of the inconsistent results from the perspectives of individual differences and varying approaches to OT administration, and shed light on the underlying mechanisms of OT. Ultimately, standardization of dosage, frequency of administration, formulation characteristics, and nasal spray devices is proposed as essential for future human studies and clinical applications of OT treatment.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171211"},"PeriodicalIF":3.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140347922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Body weight modulates the impact of oxytocin on chronic cold-immobilization stress response 体重可调节催产素对慢性冷动应激反应的影响

IF 3 4区医学

Peptides Pub Date : 2024-03-30 DOI: 10.1016/j.peptides.2024.171202

Deniz Önal , Hilal Korkmaz , Gizem Önal , Bilge Pehlivanoğlu

{"title":"Body weight modulates the impact of oxytocin on chronic cold-immobilization stress response","authors":"Deniz Önal , Hilal Korkmaz , Gizem Önal , Bilge Pehlivanoğlu","doi":"10.1016/j.peptides.2024.171202","DOIUrl":"10.1016/j.peptides.2024.171202","url":null,"abstract":"<div><p>By activating the stress system, stress modulates various physiological parameters including food intake, energy consumption, and, consequently, body weight. The role of oxytocin in the regulation of stress and obesity cannot be disregarded. Based on these findings, we aimed to investigate the effect of intranasal oxytocin on stress response in high-fat-diet (HFD)--fed and control-diet-fed rats exposed to chronic stress. Cold-immobilization stress was applied for 5 consecutive days to male Sprague-Dawley rats fed either with a control diet (n=20) or HFD (n=20) for 6 weeks. Half of the animals in each group received oxytocin. Stress response was evaluated via plasma and salivary cortisol levels as well as elevated plus maze scores. Prefrontal cortex and hypothalamic oxytocin receptor (OxtR) expression levels were identified using western blot analysis. The results showed higher stress response in HFD-fed animals than in control animals both under basal and post-stress conditions. Oxytocin application had a prominent anxiolytic effect in the control group but an insignificant effect in the HFD group. While OxtR expression levels in the prefrontal cortex did not vary according to the body weight and oxytocin application, OxtR levels in the hypothalamus were higher in the HFD- and/or oxytocin-treated animals. Our results indicated that the peripheral and central effects of oxytocin vary with body weight. Moreover, obesity masks the anxiolytic effects of oxytocin, probably by reinforcing the stress condition via central OxtRs. In conclusion, elucidating the mechanisms underlying the central effect of oxytocin is important to cope with stress and obesity.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171202"},"PeriodicalIF":3.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140331954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysfunction of the renin-angiotensin-aldosterone system in human septic shock 人类脓毒性休克中肾素-血管紧张素-醛固酮系统的功能障碍。

IF 3 4区医学

Peptides Pub Date : 2024-03-29 DOI: 10.1016/j.peptides.2024.171201

Christopher L. Schaich , Daniel E. Leisman , Marcia B. Goldberg , Micheal R. Filbin , Ashish K. Khanna , Mark C. Chappell

{"title":"Dysfunction of the renin-angiotensin-aldosterone system in human septic shock","authors":"Christopher L. Schaich , Daniel E. Leisman , Marcia B. Goldberg , Micheal R. Filbin , Ashish K. Khanna , Mark C. Chappell","doi":"10.1016/j.peptides.2024.171201","DOIUrl":"10.1016/j.peptides.2024.171201","url":null,"abstract":"<div><p>Sepsis and septic shock are global healthcare problems associated with mortality rates of up to 40% despite optimal standard-of-care therapy and constitute the primary cause of death in intensive care units worldwide. Circulating biomarkers of septic shock severity may represent a clinically relevant approach to individualize those patients at risk for worse outcomes early in the course of the disease, which may facilitate early and more precise interventions to improve the clinical course. However, currently used septic shock biomarkers, including lactate, may be non-specific and have variable impact on prognosis and/or disease management. Activation of the renin-angiotensin-aldosterone system (RAAS) is likely an early event in septic shock, and studies suggest that an elevated level of renin, the early and committed step in the RAAS cascade, is a better predictor of worse outcomes in septic shock, including mortality, than the current standard-of-care measure of lactate. Despite a robust increase in renin, other elements of the RAAS, including endogenous levels of Ang II, may fail to sufficiently increase to maintain blood pressure, tissue perfusion, and protective immune responses in septic shock patients. We review the current clinical literature regarding the dysfunction of the RAAS in septic shock and potential therapeutic approaches to improve clinical outcomes.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171201"},"PeriodicalIF":3.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140331955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut 免疫调节与炎症：肠道内 GLP-1R 和 GIPR 表达细胞的作用

IF 3 4区医学

Peptides Pub Date : 2024-03-28 DOI: 10.1016/j.peptides.2024.171200

Nadya M. Morrow , Arianne Morissette , Erin E. Mulvihill

{"title":"Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut","authors":"Nadya M. Morrow , Arianne Morissette , Erin E. Mulvihill","doi":"10.1016/j.peptides.2024.171200","DOIUrl":"10.1016/j.peptides.2024.171200","url":null,"abstract":"<div><p>Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are peptide hormones produced by enteroendocrine cells in the small intestine. Despite being produced in the gut, the leveraging of their role in potentiating glucose-stimulated insulin secretion, also known as the incretin effect, has distracted from discernment of direct intestinal signaling circuits. Both preclinical and clinical evidence have highlighted a role for the incretins in inflammation. In this review, we highlight the discoveries of GLP-1 receptor (GLP-1R)+ natural (TCRαβ and TCRγδ) and induced (TCRαβ+CD4+ cells and TCRαβ+CD8αβ+) intraepithelial lymphocytes. Both endogenous signaling and pharmacological activation of GLP-1R impact local and systemic inflammation, the gut microbiota, whole-body metabolism, as well as the control of GLP-1 bioavailability. While GIPR signaling has been documented to impact hematopoiesis, the impact of these bone marrow-derived cells in gut immunology is not well understood. We uncover gaps in the literature of the evaluation of the impact of sex in these GLP-1R and GIP receptor (GIPR) signaling circuits and provide speculations of the maintenance roles these hormones play within the gut in the fasting-refeeding cycles. GLP-1R agonists and GLP-1R/GIPR agonists are widely used as treatments for diabetes and weight loss, respectively; however, their impact on gut homeostasis has not been fully explored. Advancing our understanding of the roles of GLP-1R and GIPR signaling within the gut at homeostasis as well as metabolic and inflammatory diseases may provide targets to improve disease management.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171200"},"PeriodicalIF":3.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Lessons from the gut: Studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy 来自肠道的新启示：研究肠道肽在胃旁路术和袖状胃切除术后体重减轻和糖尿病缓解中的作用。

IF 3 4区医学

Peptides Pub Date : 2024-03-27 DOI: 10.1016/j.peptides.2024.171199

Jens Juul Holst , Sten Madsbad , Kirstine Nyvold Bojsen-Møller , Carsten Dirksen , Maria Svane

{"title":"New Lessons from the gut: Studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy","authors":"Jens Juul Holst , Sten Madsbad , Kirstine Nyvold Bojsen-Møller , Carsten Dirksen , Maria Svane","doi":"10.1016/j.peptides.2024.171199","DOIUrl":"10.1016/j.peptides.2024.171199","url":null,"abstract":"<div><p>It has been known since 2005 that the secretion of several gut hormones changes radically after gastric bypass operations and, although more moderately, after sleeve gastrectomy but not after gastric banding. It has therefore been speculated that increased secretion of particularly GLP-1 and Peptide YY (PYY), which both inhibit appetite and food intake, may be involved in the weight loss effects of surgery and for improvements in glucose tolerance. Experiments involving inhibition of hormone secretion with somatostatin, blockade of their actions with antagonists, or blockade of hormone formation/activation support this notion. However, differences between results of bypass and sleeve operations indicate that distinct mechanisms may also be involved. Although the reductions in ghrelin secretion after sleeve gastrectomy would seem to provide an obvious explanation, experiments with restoration of ghrelin levels pointed towards effects on insulin secretion and glucose tolerance rather than on food intake. It seems clear that changes in GLP-1 secretion are important for insulin secretion after bypass and appear to be responsible for postbariatric hypoglycemia in glucose-tolerant individuals; however, with time the improvements in insulin sensitivity, which in turn are secondary to the weight loss, may be more important. Changes in bile acid metabolism do not seem to be of particular importance in humans.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171199"},"PeriodicalIF":3.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0196978124000524/pdfft?md5=72ecfed8ae45027b259cb41803b79a0e&pid=1-s2.0-S0196978124000524-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of energy metabolism through central GIPR signaling 通过中枢 GIPR 信号调节能量代谢。

IF 3 4区医学

Peptides Pub Date : 2024-03-26 DOI: 10.1016/j.peptides.2024.171198

Arkadiusz Liskiewicz , Timo D. Müller

{"title":"Regulation of energy metabolism through central GIPR signaling","authors":"Arkadiusz Liskiewicz , Timo D. Müller","doi":"10.1016/j.peptides.2024.171198","DOIUrl":"10.1016/j.peptides.2024.171198","url":null,"abstract":"<div><p>In recent years, significant progress has been made to pharmacologically combat the obesity pandemic, particularly with regard to biochemically tailored drugs that simultaneously target the receptors for glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP). But while the pharmacological benefits of GLP-1 receptor (GLP-1R) agonism are widely acknowledged, the role of the GIP system in regulating systems metabolism remains controversial. When given in adjunct to GLP-1R agonism, both agonism and antagonism of the GIP receptor (GIPR) improves metabolic outcome in preclinical and clinical studies, and despite persistent concerns about its potential obesogenic nature, there is accumulating evidence indicating that GIP has beneficial metabolic effects via central GIPR agonism. Nonetheless, despite growing recognition of the GIP system as a valuable pharmacological target, there remains great uncertainty as to where and how GIP acts in the brain to regulate metabolism, and how GIPR agonism may differ from GIPR antagonism in control of energy metabolism. In this review we highlight current knowledge on the central action of GIP, and discuss open questions related to its multifaceted biology in the brain and the periphery.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171198"},"PeriodicalIF":3.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140288709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA regulation of islet and enteroendocrine peptides: Physiology and therapeutic implications for type 2 diabetes 胰岛和肠内分泌肽的微RNA调控：2 型糖尿病的生理学和治疗学意义。

IF 3 4区医学

Peptides Pub Date : 2024-03-15 DOI: 10.1016/j.peptides.2024.171196

E.R. Carr , P.B. Higgins , N.H. McClenaghan , P.R. Flatt , A.G. McCloskey

{"title":"MicroRNA regulation of islet and enteroendocrine peptides: Physiology and therapeutic implications for type 2 diabetes","authors":"E.R. Carr , P.B. Higgins , N.H. McClenaghan , P.R. Flatt , A.G. McCloskey","doi":"10.1016/j.peptides.2024.171196","DOIUrl":"10.1016/j.peptides.2024.171196","url":null,"abstract":"<div><p>The pathogenesis of type 2 diabetes (T2D) is associated with dysregulation of glucoregulatory hormones, including both islet and enteroendocrine peptides. Microribonucleic acids (miRNAs) are short noncoding RNA sequences which post transcriptionally inhibit protein synthesis by binding to complementary messenger RNA (mRNA). Essential for normal cell activities, including proliferation and apoptosis, dysregulation of these noncoding RNA molecules have been linked to several diseases, including diabetes, where alterations in miRNA expression within pancreatic islets have been observed. This may occur as a compensatory mechanism to maintain beta-cell mass/function (e.g., downregulation of miR-7), or conversely, lead to further beta-cell demise and disease progression (e.g., upregulation of miR-187). Thus, targeting miRNAs has potential for novel diagnostic and therapeutic applications in T2D. This is reinforced by the success seen to date with miRNA-based therapeutics for other conditions currently in clinical trials. In this review, differential expression of miRNAs in human islets associated with T2D will be discussed along with further consideration of their effects on the production and secretion of islet and incretin hormones. This analysis further unravels the therapeutic potential of miRNAs and offers insights into novel strategies for T2D management.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171196"},"PeriodicalIF":3.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0196978124000494/pdfft?md5=66719a82b03af58c6708975250c73b64&pid=1-s2.0-S0196978124000494-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic pramlintide decreases feeding via a reduction in meal size in male rats 慢性普拉克林肽可通过减少雄性大鼠的进食量来减少进食量。

IF 3 4区医学

Peptides Pub Date : 2024-03-15 DOI: 10.1016/j.peptides.2024.171197

Katherine A. Kern , Adrianne M. DiBrog , Kiran Kaur , Johnathan T. Przybysz , Elizabeth G. Mietlicki-Baase

{"title":"Chronic pramlintide decreases feeding via a reduction in meal size in male rats","authors":"Katherine A. Kern , Adrianne M. DiBrog , Kiran Kaur , Johnathan T. Przybysz , Elizabeth G. Mietlicki-Baase","doi":"10.1016/j.peptides.2024.171197","DOIUrl":"10.1016/j.peptides.2024.171197","url":null,"abstract":"<div><p>Amylin, a pancreatic hormone, is well-established to suppress feeding by enhancing satiation. Pramlintide, an amylin analog that is FDA-approved for the treatment of diabetes, has also been shown to produce hypophagia. However, the behavioral mechanisms underlying the ability of pramlintide to suppress feeding are unresolved. We hypothesized that systemic pramlintide administration in rats would reduce energy intake, specifically by reducing meal size. Male rats were given b.i.d. administration of intraperitoneal pramlintide or vehicle for 1 week, and chow intake, meal patterns, and body weight were monitored throughout the test period. Consistent with our hypothesis, pramlintide decreased chow intake mainly via suppression of meal size, with corresponding reductions in meal duration on several days. Fewer effects on meal number or feeding rate were detected. Pramlintide also reduced weight gain over the 1-week study. These results highlight that the behavioral mechanisms by which pramlintide produces hypophagia are similar to those driven by amylin itself, and provide important insight into the ability of this pharmacotherapy to promote negative energy balance over a period of chronic administration.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171197"},"PeriodicalIF":3.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0